Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on August 6, 2025
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior year Second Quarter 2025 …
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
GlobeNewswire
·
August 6, 2025
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year …
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
GlobeNewswire
·
August 6, 2025
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) …
New Agreement Brings Breakthrough Dyslipidemia Treatment to Saudi Arabia and MEA
EIN Presswire
·
August 6, 2025
Strategic partnership between Jamjoom Pharma and Althera Laboratories will bring an innovative, dual-action cholesterol therapy to the region. DUBLIN, DUBLIN, IRELAND, August 6, 2025 /EINPresswire.com/ -- Jamjoom Pharma, a leading Saudi pharmaceutical …
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
GlobeNewswire
·
August 6, 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a …
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
GlobeNewswire
·
August 6, 2025
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with …
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
·
August 6, 2025
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash …
electroCore Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to host a conference …
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
GlobeNewswire
·
August 6, 2025
BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), …
Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
GlobeNewswire
·
August 6, 2025
Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a …
HilleVax Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second …
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
GlobeNewswire
·
August 6, 2025
ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell …
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
GlobeNewswire
·
August 6, 2025
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful …
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted EBITDA(1) of $50.8 Million, a 59% YoY Increase …
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
GlobeNewswire
·
August 6, 2025
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical …
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
GlobeNewswire
·
August 6, 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further …
AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance
GlobeNewswire
·
August 6, 2025
Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic. The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance …
Cytek Biosciences Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second …
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, …